ATC Group: N06BA04 Methylphenidate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06BA04 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics
4 N06BA Centrally acting sympathomimetics
5 N06BA04 Methylphenidate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 30 mg

Active ingredients in N06BA04

Active Ingredient

Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space.

Related product monographs

Document Type Information Source  
 CONCERTA Extended-release tablet MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)
 CONTRAMYL Prolonged release tablet MPI, Generic Health Products Regulatory Authority (ZA)
 DELMOSART Prolonged-release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 EQUASYM Modified release capsule, hard MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MATORIDE XR Prolonged-release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MEDIKINET Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RADD Prolonged-release tablet MPI, Generic Health Products Regulatory Authority (ZA)
 RITALIN Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 RUBIFEN Immediate release tablet, Sustained release tablet MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)

United States medicines

Medicines classified under this ATC code globally

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.